Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308118979> ?p ?o ?g. }
- W4308118979 endingPage "13359" @default.
- W4308118979 startingPage "13359" @default.
- W4308118979 abstract "Myotonic dystrophy type 1 (DM1) is a dominant genetic disease in which the expansion of long CTG trinucleotides in the 3′ UTR of the myotonic dystrophy protein kinase (DMPK) gene results in toxic RNA gain-of-function and gene mis-splicing affecting mainly the muscles, the heart, and the brain. The CUG-expanded transcripts are a suitable target for the development of antisense oligonucleotide (ASO) therapies. Various chemical modifications of the sugar-phosphate backbone have been reported to significantly enhance the affinity of ASOs for RNA and their resistance to nucleases, making it possible to reverse DM1-like symptoms following systemic administration in different transgenic mouse models. However, specific tissue delivery remains to be improved to achieve significant clinical outcomes in humans. Several strategies, including ASO conjugation to cell-penetrating peptides, fatty acids, or monoclonal antibodies, have recently been shown to improve potency in muscle and cardiac tissues in mice. Moreover, intrathecal administration of ASOs may be an advantageous complementary administration route to bypass the blood-brain barrier and correct defects of the central nervous system in DM1. This review describes the evolution of the chemical design of antisense oligonucleotides targeting CUG-expanded mRNAs and how recent advances in the field may be game-changing by forwarding laboratory findings into clinical research and treatments for DM1 and other microsatellite diseases." @default.
- W4308118979 created "2022-11-08" @default.
- W4308118979 creator A5002341975 @default.
- W4308118979 creator A5005534121 @default.
- W4308118979 creator A5020010287 @default.
- W4308118979 creator A5036673188 @default.
- W4308118979 creator A5043092391 @default.
- W4308118979 creator A5084218012 @default.
- W4308118979 date "2022-11-01" @default.
- W4308118979 modified "2023-10-09" @default.
- W4308118979 title "Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1" @default.
- W4308118979 cites W1212882679 @default.
- W4308118979 cites W135466628 @default.
- W4308118979 cites W1510644906 @default.
- W4308118979 cites W1524922819 @default.
- W4308118979 cites W1555409852 @default.
- W4308118979 cites W1653978584 @default.
- W4308118979 cites W1919521444 @default.
- W4308118979 cites W1964008557 @default.
- W4308118979 cites W1965093586 @default.
- W4308118979 cites W1967470178 @default.
- W4308118979 cites W1972453061 @default.
- W4308118979 cites W1972746334 @default.
- W4308118979 cites W1984539641 @default.
- W4308118979 cites W1986425431 @default.
- W4308118979 cites W1987578671 @default.
- W4308118979 cites W1990059209 @default.
- W4308118979 cites W1991948602 @default.
- W4308118979 cites W1992609622 @default.
- W4308118979 cites W1995964547 @default.
- W4308118979 cites W1996064016 @default.
- W4308118979 cites W2000277299 @default.
- W4308118979 cites W2001607290 @default.
- W4308118979 cites W2002089022 @default.
- W4308118979 cites W2003642545 @default.
- W4308118979 cites W2004232523 @default.
- W4308118979 cites W2004851279 @default.
- W4308118979 cites W2004901342 @default.
- W4308118979 cites W2006998980 @default.
- W4308118979 cites W2008578937 @default.
- W4308118979 cites W2008897130 @default.
- W4308118979 cites W2011049276 @default.
- W4308118979 cites W2013080285 @default.
- W4308118979 cites W2014921813 @default.
- W4308118979 cites W2019818589 @default.
- W4308118979 cites W2022949306 @default.
- W4308118979 cites W2022996403 @default.
- W4308118979 cites W2030234137 @default.
- W4308118979 cites W2031135436 @default.
- W4308118979 cites W2033425827 @default.
- W4308118979 cites W2037695327 @default.
- W4308118979 cites W2039944783 @default.
- W4308118979 cites W2041385249 @default.
- W4308118979 cites W2050578408 @default.
- W4308118979 cites W2061092005 @default.
- W4308118979 cites W2063915751 @default.
- W4308118979 cites W2065032657 @default.
- W4308118979 cites W2071230707 @default.
- W4308118979 cites W2072049133 @default.
- W4308118979 cites W2073289591 @default.
- W4308118979 cites W2076324093 @default.
- W4308118979 cites W2077237334 @default.
- W4308118979 cites W2077301034 @default.
- W4308118979 cites W2081400741 @default.
- W4308118979 cites W2081748748 @default.
- W4308118979 cites W2081918359 @default.
- W4308118979 cites W2082965230 @default.
- W4308118979 cites W2084091637 @default.
- W4308118979 cites W2088707712 @default.
- W4308118979 cites W2088712414 @default.
- W4308118979 cites W2095143079 @default.
- W4308118979 cites W2099039583 @default.
- W4308118979 cites W2102099323 @default.
- W4308118979 cites W2104580096 @default.
- W4308118979 cites W2108811540 @default.
- W4308118979 cites W2109385021 @default.
- W4308118979 cites W2113918626 @default.
- W4308118979 cites W2114775015 @default.
- W4308118979 cites W2116009187 @default.
- W4308118979 cites W2118121529 @default.
- W4308118979 cites W2131325142 @default.
- W4308118979 cites W2131447660 @default.
- W4308118979 cites W2133696920 @default.
- W4308118979 cites W2133876293 @default.
- W4308118979 cites W2134668315 @default.
- W4308118979 cites W2135118216 @default.
- W4308118979 cites W2135809925 @default.
- W4308118979 cites W2139273728 @default.
- W4308118979 cites W2140472095 @default.
- W4308118979 cites W2141124826 @default.
- W4308118979 cites W2141382475 @default.
- W4308118979 cites W2141427674 @default.
- W4308118979 cites W2142169677 @default.
- W4308118979 cites W2146308704 @default.
- W4308118979 cites W2147017969 @default.
- W4308118979 cites W2148320915 @default.
- W4308118979 cites W2148833175 @default.
- W4308118979 cites W2150948543 @default.